Raloxifene Has No Efficacy in Reducing the High Bone Turnover and the Risk of Spontaneous Vertebral Fractures after Denosumab Discontinuation.

Détails

Ressource 1Télécharger: Raloxifène-fxvl 2018-CasesRepRheumatol.pdf (1514.48 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY 4.0
ID Serval
serval:BIB_E25ED86031BF
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Etude de cas (case report): rapporte une observation et la commente brièvement.
Collection
Publications
Titre
Raloxifene Has No Efficacy in Reducing the High Bone Turnover and the Risk of Spontaneous Vertebral Fractures after Denosumab Discontinuation.
Périodique
Case reports in rheumatology
Auteur(s)
Gonzalez-Rodriguez E., Stoll D., Lamy O.
ISSN
2090-6889 (Print)
ISSN-L
2090-6897
Statut éditorial
Publié
Date de publication
2018
Peer-reviewed
Oui
Volume
2018
Pages
5432751
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: epublish
Résumé
At denosumab discontinuation, an antiresorptive agent is prescribed to reduce the high bone turnover, the rapid bone loss, and the risk of spontaneous vertebral fractures. We report the case of a woman treated with aromatase inhibitors and denosumab for 5 years. Raloxifene was then prescribed to prevent the rebound effect. Raloxifene was ineffective to reduce the high bone turnover and to avoid spontaneous clinical vertebral fractures. We believe that among the antiresorptive treatments, the most powerful bisphosphonates should be favored, and their administration adapted according to the serial follow-up of bone markers.
Pubmed
Open Access
Oui
Création de la notice
17/10/2018 9:32
Dernière modification de la notice
21/08/2019 6:10
Données d'usage